LiquiVent gene delivery systems - Alliance Pharmaceutical CorporationAlternative Names: LiquiVent®
Latest Information Update: 02 Feb 2007
At a glance
- Originator Alliance Pharmaceutical Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 02 Feb 2007 Discontinued - Preclinical for Respiratory tract disorders in USA (unspecified route)
- 29 Jun 2001 Preclinical development for Respiratory tract disorders in USA (Unknown route)